SCHEMBL3553928

SCHEMBL3553928

O=C(O)c1ccc(OCCOc2ccccc2NS(=O)(=O)c2c(F)cccc2F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.50
LMNA P02545 4/20 0.46
SLC16A3 O15427 2/20 0.43
CACNA1H O95180 2/20 0.42
CACNA1B Q00975 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
RAD52 P43351 1/20 0.42
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SENP7 Q9BQF6 2/20 0.41
CASP3 P42574 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565992 0.89 PKM (0.50) PKMLMNACACNA1HCACNA1BSMN1; SMN2
SCHEMBL3553635 0.85 PKM (0.51) PKMLMNASLC16A3CACNA1HCACNA1B
SCHEMBL3561665 0.85 CACNA1H (0.58) PKMSLC16A3CACNA1HCACNA1BTDP1
SCHEMBL3554984 0.85 PKM (0.56) PKMLMNASLC16A3CACNA1HCACNA1B
SCHEMBL3561502 0.85 PKM (0.52) PKMUSP2ALOX15TSHRMAPK1
SCHEMBL3554494 0.85 PKM (0.56) PKMLMNASLC16A3CACNA1HCACNA1B
SCHEMBL3552423 0.84 PIK3CA (0.50) PKMSLC16A3CACNA1HCACNA1BSMN1; SMN2
SCHEMBL3553979 0.84 PGR (0.48) PKMLMNASLC16A3CACNA1HCACNA1B
SCHEMBL3551102 0.83 RAD52 (0.50) PKMLMNACACNA1HCACNA1BSMN1; SMN2
SCHEMBL3563109 0.81 PKM (0.57) PKMLMNASMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 PKM 990/4885LMNA 2120/4885SLC16A3 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.